Humira, the injectable rheumatoid arthritis treatment is pictured in a pharmacy in Cambridge, Massachusetts on Wednesday, January 25, 2006. Abbott Laboratories said fourth-quarter sales were lifted by surging demand for its arthritis treatment while Bristol-Myers Squibb Co. said revenue fell as it faces a patent fight on its best-selling product. Photographer: JB Reed/Bloomberg News Credit: J.B. Reed/Bloomberg

It's official! UnitedHealth's Optum Rx pharmacy benefit manager unit will not be a haven for employers and workers who love Humira.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Allison Bell

Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.

Core and Group Health
Health Care Reform
Employee-Paid
Employer-Paid